We get excited by our clients’ successes, especially with truly breakthrough innovations. We are delighted to congratulate the team at LBT Innovations in achieving US FDA clearance for their revolutionary APAS technology.
APAS® (Automated Plate Assessment System) is a breakthrough artificial intelligence technology for the automated imaging, image analysis, interpretation and reporting of growth on microbiology culture plates after incubation.
This is the first time that such diagnostic technology has achieved US clearance for marketing. APAS combines specialist optics and hardware with state-of-the-art “machine learning” software. The novelty of APAS required extensive dialogue with the US FDA leading to a de novo classification petition and issue of a new US regulation to cover this kind of device.
Brandwood Biomedical is proud to have supported LBT Innovations throughout the entire FDA process and we are delighted to see a ground breaking Australian innovation achieve well deserved international recognition.
- Read LBT’s announcement at http://www.lbtinnovations.com/media/company-news/lbt-fda-approval/
- For more information on APAS visit http://www.lbtinnovations.com/products/apas/
Need help with regulatory strategy, preconsultation or submissions your novel technology? We offer global support for regulatory strategy, regulatory submissions, quality systems, postmarket compliance and reimbursement. Our services include provision of expert services such as biological safety and clinical evaluation reports. Contact us at email@example.com or call us on +61 2 9906 2984.